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Abstract 
Three dimensional (3D) bioprinting of multiple cell types within optimised extracellular 
matrices has the potential to more closely model the 3D environment of human physiology 
and disease than current alternatives. In this study, we used a multi-nozzle extrusion 
bioprinter to establish models of glioblastoma made up of cancer and stromal cells printed 
within matrices comprised of alginate modified with RGDS cell adhesion peptides, 
hyaluronic acid and collagen-1. Methods were developed using U87MG glioblastoma cells 
and MM6 monocyte/macrophages, whilst more disease relevant constructs contained 
glioblastoma stem cells (GSCs), co-printed with glioma associated stromal cells (GASCs) 
and microglia. Printing parameters were optimised to promote cell-cell interaction, 
avoiding the ‘caging in’ of cells due to overly dense cross-linking. Such printing had a 
negligible effect on cell viability, and cells retained robust metabolic activity and 
proliferation. Alginate gels allowed the rapid recovery of printed cell protein and RNA, and 
fluorescent reporters provided analysis of protein kinase activation at the single cell level 
within printed constructs. GSCs showed more resistance to chemotherapeutic drugs in 3D 
printed tumour constructs compared to 2D monolayer cultures, reflecting the clinical 
situation. In summary, a novel 3D bioprinting strategy is developed which allows control 
over the spatial organisation of tumour constructs for pre-clinical drug sensitivity testing 
and studies of the tumour microenvironment. 
Keywords: 3D bioprinting, glioblastoma, cancer model, drug sensitivity, tumour 
microenvironment 
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Introduction 
3D cell culture 
Experiments conducted using human cells in simple adherent culture are often criticised 
because cells do not behave as they would in the body. On the other hand, most 
experiments cannot be conducted in humans and experiments conducted in mammals are 
expensive and often suffer criticism on ethical and scientific grounds. Therefore, as 
techniques to produce human cells with specific modified genomes and specific states of 
differentiation have progressed over recent years, the need has increased for flexible 
methods to recreate the numerous complex three dimensional environments within the 
human body. Extensive reviews have recently addressed the different approaches to the 
3D culture of human cells without an adhesive substrate (Alhaque et al., 2018; Duval et 
al., 2017). Here we will discuss very briefly the options available for 3D cell culture and 
their advantages and disadvantages before focusing on 3D bioprinting as a method to 
develop more disease relevant tumour models and which can be used in combination with 
these existing approaches. 
 
Spheroids and scaffold/matrix free 3D cultures 
 
Perhaps the simplest forms of 3D culture are those in which cultured cells are incubated in 
liquid media without any adhesive substrate, encouraging them to self-aggregate. This 
can be achieved using either curved surfaces of materials to which cells adhere very 
poorly or allowing cells to settle by gravity onto an air-liquid interface in ‘hanging drop’ 
cultures. In these conditions, many cell types will aggregate to form dense colonies often 
termed spheroids and in some cases co-cultured cell types will self-organise (Fennema et 
al., 2013; Lazzari et al., 2018; Loessner et al., 2013; Tigyi et al., 2019). These methods 
provide a simple economical route to 3D cultures, and cell show gene expression patterns 
closer to their in vivo state (Chen et al., 2017), but many cell types show little or no self-
aggregation and many other aspects of the in vivo environment are lacking. 
 
Single cell or oligocellular 3D gel cultures 
 
Techniques developed in the 1980s and 1990s have entered widespread use to study 
specific cell types in a more physiologically relevant environment through their simple 
suspension in extracellular gel matrices. This allows cells to proliferate, forming cell-cell 
and/or cell-matrix contacts in all orientations and in some cases develop structured 3D 
mini-tissues. Ease of use has led to many experiments, particularly simple cancer cell 3D 
colony formation assays, being conducted in gels formed of materials not found in the 
human body and with which our cells do not strongly interact, such as the seaweed-
derived polysaccharide agarose. However, this lack of receptor engagement of human 
cells with these matrices limits the usefulness of these cultures. On the other hand, the 
approaches most commonly used involve the suspension of cells in materials rich in 
mammalian extracellular matrix proteins such as collagen and laminin (e.g. Matrigel). 
Suspension in gels containing physiologically relevant extracellular ligands promotes gene 
expression patterns closer to those observed in vivo (Stankevicius et al., 2016; Tibarewal 
et al., 2012) and in some cases directs physiological cell polarisation and 3D tissue 
architectures such as the formation by epithelial cell lines of hollow acini and tubules 
(Berglund et al., 2013; Schmeichel and Bissell, 2003; Zegers et al., 2003).  
 
Organoids: multipotent cell lines producing distinct spatially organised cell types. 
 
The term organoid has been used for many decades to describe a variety of cultures and 
explants from different cells and organs as well as being a term used for some 
intracellular organelles (Simian and Bissell, 2017). As early as the 1980s, it was used to 
describe a colonic cell line which would differentiate into multiple cell types forming crypt-
like structures in vitro (Whitehead et al., 1987). However, interest in what we now call 
organoids has blossomed in the last decade with the definition of procedures to 
consistently isolate cell lines with stem cell like properties from many healthy and 
diseased tissues. These cells which are multipotent in vitro and their methods of culture, 
were first optimised for intestinal epithelia. In this case, stem-like cells, either isolated as 
single cells or present in very small tissue fragments, give rise to spatially organised 
structures resembling the colonic epithelium and containing several distinct cell types 
(Sato et al., 2009). These cultures are termed organoids, and analogous lines, giving rise 
in culture to spatially organised mini-organs have now been isolated from many healthy 
tissue sources, including the colon, small intestine, stomach, oesophagus, pancreas, 
prostate, liver, brain and many other tissues (Clevers, 2016; Simian and Bissell, 2017). In 
addition, mutant lines can be isolated from diseased tissues, providing an excellent 
opportunity to model these conditions in vitro. On the other hand, in many cases the 
spatial organisation found in healthy tissues and often retained in the originating clinical 
samples appears to be lost in derived cultures. 
Organoid cultures provide the opportunity to study and manipulate cells with defined 
genetics in vitro with much more physiological tissue organisation and gene expression 
profiles than previous culture approaches. Accordingly, uptake of these methods has been 
very rapid, both in the study of physiology and pathology and even in drug testing. On the 
other hand, one drawback of these culture approaches is their reliance on poorly defined 
biological extracts (e.g. Matrigel) and numerous protein additives which make these 
experiments expensive. The cell types produced in organoid cultures are also limited to 
those produced by each multipotent stem cell type and therefore, for example, tumour 
organoids lack immune cells, vasculature and other stromal cell types. 
 
Organotypic 3D cultures 
 
Many other examples of complex spatially organised 3D cultures incorporating multiple 
cell types have been described (Shamir and Ewald, 2014). Some of these methods, such 
as brain slices, rely almost exclusively on the existing complex organisation of multiple cell 
lineages within explanted tissues. In these cases, manipulation is limited to steps such as 
the injection of specific exogenous cells (e.g. brain tumour cells into brain slices) or 
manipulation of gene expression by transfection or viral transduction of cell populations 
within these cultures. 
Alternatively, methods such as layered skin cultures rely on the active experimental 
positioning of specific cell populations, potentially including defined or manipulated cells. 
Many of this type of organotypic culture rely on cells which will form layers in vitro 
replicating in vivo biology due to the experimental ease with which reproducible cultures 
can be prepared. A more recent extension of this approach is the use of 3D printers to 
position cells in more complex 3D spatial arrangements, extending the number of tissues 
and organs which can be prepared. 
 
3D bioprinting 
 
The term 3D bioprinting currently refers to the construction of three dimensional spatially 
designed constructs by the sequential deposition of layers of biomaterials which represent 
potential extracellular matrices which are either pre-mixed with live cells or are then 
cellularised after printing. This produces computer designed constructs containing live 
cells and has led to intense research in areas where specific precise 3D structure is 
critical, such as the manufacture of grafts of cartilage and bone for transplant surgery 
(Roseti et al., 2018). 3D bioprinting is currently limited by several factors. These include 
the need for printing biomaterials which have both the mechanical properties required for 
printing and the physiological properties required in printed tissues, the need to improve 
the resolution of printing, in terms of the smallest features or domains with a construct and 
also the current inability to introduce appropriate vasculature within constructs. However, 
there is great research interest in the potential of 3D bioprinting to provide flexible 
hardware and methods to rapidly generate many different user-defined diverse spatially 
detailed 3D cultures containing numerous different cell types and matrices (Heinrich et al., 
2019). Bioprinting also provides opportunities for automation and the production of large 
numbers of replicate 3D models for basic science and for drug testing. Therefore it seems 
likely to be an increasingly common practice, and importantly, bioprinting technology can 
be combined with the approaches above, e.g. printing spheroids or fabricating organotypic 
cultures. Notably, the first studies combining the self-organising capabilities of organoids 
with the operator designed possibilities of bioprinting are emerging (Reid et al., 2018).  
 
Experimental models of Glioblastoma 
 
Brain tumours as a group have amongst the worst outcomes of any type of cancer 
(Quaresma et al., 2015). This is particularly true of glioblastoma, the most common 
malignant adult brain cancer, with 10 year survival rates below 1% (Tykocki and Eltayeb, 
2018). Improving the treatment of glioblastoma is made more difficult both by the lack of 
pre-clinical experimental systems which accurately predict drug responses in patients and 
by poor understanding of the complex multicomponent environment within these tumours. 
Both problems motivate efforts to develop better disease models and given the challenges 
of minimising suffering caused by tumour growth in the brain of study animals, there is a 
strong push towards in vitro models. 
Glioblastomas contain cancer stem cells and more differentiated cancer cells with less 
capacity for self-renewal (Chen et al., 2012; Jackson et al., 2015; Singh et al., 2003). 
These tumours also contain stromal cells such as microglia and other macrophages, 
microvascular endothelial cells and glioblastoma-associated stromal cells within a 
complex heterogeneous extracellular matrix (Barros et al., 2011; Charles et al., 2012; 
Clavreul et al., 2014). In many tumour types including glioblastoma, it appears that tumour 
stromal cells and the acellular components of the tumour niche modulate tumour 
development and drug responses (Charles et al., 2012; Cheng et al., 2013; Shi et al., 
2017). Therefore, pharmaceutical targeting of these microenvironmental compartments, 
including efforts to enhance the immune destruction of cancer cells, is becoming a major 
strategy in the treatment of many cancers such as glioblastoma (Boussiotis and Charest, 
2018; Guerra et al., 2018; Kurz and Wen, 2018; Valkenburg et al., 2018). 
The importance of three-dimensional models to study cancer biology and drug responses 
has been clear for a long time, with numerous studies deriving data from 3D culture which 
are closer to clinical data and animal data than those derived from adherent cell cultures 
(Schmeichel and Bissell, 2003; Xu et al., 2014; Yamada and Cukierman, 2007). Cell 
morphology, cell-cell and cell-matrix interaction, cell signalling, gene expression (Chen et 
al., 2017; Ramos et al., 2018), differentiation and drug responses are all frequently 
different in 2D and 3D cultures (Baker and Chen, 2012; Jhanwar-Uniyal et al., 2013; 
Jhanwar-Uniyal et al., 2019; Thoma et al., 2014). Additionally, in the rare cases in which 
adherent cell culture models incorporate stromal cells and extracellular matrix 
components, the way in which these factors interact with tumour cells is very different in 
2D monolayers from circumstances in vivo or in 3D culture. 
3D printing, also termed additive manufacture, is the sequential deposition of layers of 
material at specified positions to build potentially complex 3D structures. In recent years 
there has been substantial interest in the 3D printing of live cells as a potential solution to 
the flexible creation of diverse engineered tissues both for regenerative/reparative 
medicine and to generate custom disease models (Derby, 2012; Knowlton et al., 2015; 
Murphy and Atala, 2014). 3D printing live cells within an optimised extracellular matrix 
(bioprinting) can provide high spatial precision in the non-uniform deposition of multiple 
cells and matrix components and additionally allows high cell densities and construct 
reproducibility. The first application of this method using cancer cells was the 3D 
bioprinting of Hela cell constructs in 2014 (Zhao et al., 2014) but other studies have 
followed (Dai et al., 2016; Jiang et al., 2017). 
Several 3D bioprinting hardware platforms have been developed each with advantages 
and limitations which have been recently reviewed (Li et al., 2016). Here we have further 
developed our recent extrusion printing method (Tabriz et al., 2015) and applied this to 
produce multilineage glioblastoma models. This robust and flexible 3D bioprinting strategy 
allows the testing of drug sensitivity and the analysis of stromal cell influence on tumor cell 
signaling at the single level through the use of fluorescence protein kinase reporters. 
  
Materials and Methods 
Bioink preparation 
G-rich alginate powder (Protanal LF 10/60 FT, FMC Biopolymers) as well as RGDS-
Alginate were sterilised by exposure to UV light for 3 hours. Cross-linking reagents, CaCl2 
and BaCl2 (Sigma Aldrich, Gillingham, Dorset, UK) were prepared in milliQ water adjusting 
the osmolarity of each solution to 330 mOsm/L and pH to 7.4. Cross-linking solutions were 
sterilised by filtering. 
Alginate modification 
RGDS-Alginate was synthesised using carbodiimide chemistry based on previous 
publications (Rowley et al., 1999). Briefly, a 1% solution of alginate in 100 mM MES, 
pH6.8 was activated using 10 mM Sulfo-NHS (Sigma Aldrich) and 9 mM EDC (Alfa 
Aesar). Then, RGDS peptide (Alfa Aesar, Heysham, UK) was added (0.01% w/v or 1% of 
alginate mass) and the reaction stirred for 1 h. The solution was then dialysed against 
Milli-Q water using a 3.5 kDa MW membrane cassette (Thermo Fisher, Loughborough, 
UK) for 3 days with 8 water changes. After dialysis, RGDS-Alginate was precipitated by 
adding ethanol to 70% volume and washed several times with more ethanol. The modified 
alginate was then further purified by treating it with chloroform and activated charcoal. The 
solid was then freeze dried. The same reaction was performed for fluorescein alginate by 
adding 10 mM 5-aminofluorescein (Sigma Aldrich) in place of the RGDS peptide. Purity of 
alginate, G/M ratio and conjugation efficiency were assessed using 1H-NMR in a Bruker 
AVIII400 with water suppression; high power 1H pulse of 10 μs at -1.83 dB; number of 
scans 256 with a relaxation delay of 1 s and acquisition time of 1 s. Line broadening 1 Hz. 
Dynamic mechanical analysis 
3D hydrogel structures with a diameter of 3±0.5 mm and a height of 5±0.5 mm was 
prepared from 400 µL of printing material, consisting of specific percentages of RGD-
alginate, hyaluronic acid (Thermo Fisher) and collagen-1 (Collagen Solutions, Glasgow, 
UK) with 10,000 cell/ µL. Calcium chloride (0 - 50 mM) was used as crosslinking agent for 
3 minutes. Compression tests were performed in triplicate on a 2980 DMA (TA 
Instruments, New Castle, DE, USA) with a ramp force from 0.1–1 N for 10 min, at room 
temperature. The elastic modulus was calculated as the slope of the stress-strain curve 
that was obtained from the compression test. 
3D Bioprinting 
3D bioprinting was performed by extrusion using either a modified open-source 
Fab@Home dual syringe printer (Tabriz et al., 2015) or a pre-prototype extrusion 
bioprinter provided by Renishaw PLC (Edinburgh, UK), with an 8-valve syringe pump and 
a single print head mounted with up to 6 extrusion delivery lines and nozzles that can 
deposit up to 6 different independent bioinks or materials required for bioprinting, such as 
divalent cation solutions. Unless specified, a 200 μm diameter steel conical nozzle was 
used. A hydrophobic and conical nozzle promoted consistent deposition while minimising 
the shear stress on the cells being ejected. 
Cell culture 
In this study, prior to printing, cells were grown in standard adherent cell culture. Human 
glioblastoma (U87MG, ECACC) and monocytic (MM6, Mono-Mac-6, David Brown; School 
of Life Sciences, Heriot-Watt University) cell lines were cultured in minimum essential 
medium (MEM) supplemented with 10% (v/v) foetal bovine serum (FBS), 2 mM L-
glutamine, 1x non-essential amino acid mix (NEAA, Gibco Thermo-Fisher), and 1 mM 
sodium pyruvate. Human embryonic kidney 293T (HEK293T), MDA-MB-231, MDA-MB-
468, 1321N1 and FLO-1 cells were maintained in Dulbecco Modified Essential Medium 
(DMEM) supplemented with 10% (v/v) FBS, 2 mM L-Glutamine, 1x NEAA and 1 mM 
sodium pyruvate. OE33 and DBTRG.05MG cells were maintained in RPMI 1640 medium 
supplemented with 2mM glutamine and 10% FBS. Glioblastoma stem cell line (G7, G144 
and G166, provided by Steve Pollard; MRC Centre for Regenerative Medicine, University 
of Edinburgh (Pollard et al., 2009)) were cultured in DMEM F-12 (Sigma Aldrich) 
supplemented with 8 mM glucose (Sigma Aldrich), 1x NEAA (Gibco Thermo Fisher), Pen-
strep, 30 mg/mL Bovine Serum Albumin Fraction V, 100 μM beta-mercaptoethanol, 
neuronal cell culture supplements B27 0.5X and N2 0.5X (Thermo Fisher Scientific) , 10 
ng/mL murine Epidermal Growth Factor and human Fibroblast Growth Factor (Peprotech, 
London W6, UK) and 1 μg/mL laminin (Sigma Aldrich). Human GASCs were provided by 
Anne Clavreul (Département de Neurochirurgie, CHU d'Angers, Angers, France) and 
cultured as previously described (Clavreul et al., 2014). Human microglia were purchased 
from Celprogen and were cultured in human microglia primary cell culture complete media 
with serum (Celprogen, York, UK). In order to activate MM-6 cells, cells were exposed to 
50 ng/mL of 12-O-Tetradecanoylphorbol 13-acetate (PMA; Sigma Aldrich) overnight. After 
24 h the cells became adherent and PMA was removed. Cells were incubated for another 
2 days and then trypsinised for bioprinting. 
Imaging of the cells was performed using either a Confocal Laser Scanning Microscope 
(Leica SP5 SMD, Leica microsystems, ESRIC imaging facility, HWU) or a modified Nikon 
two-photon microscope (CALM facility, University of Edinburgh). Data was analysed using 
Imaris software (Bitplane, Belfast, UK). 
Cell line modification 
Cells lines were modified to express fluorescent proteins and reporters by lentiviral 
transduction. cDNAs encoding fluorescent proteins were subcloned into the BamHI and 
NotI sites of the lentiviral vector pHR-SIN (Demaison et al., 2002; Ikeda et al., 2003). 
Kinase biosensors for ERK, p38, PKA and JNK expressed from lentiviral vectors (Regot et 
al., 2014) were supplied by Addgene (IDs: 59150, 59152, 59153, and 59151 respectively). 
Lentiviral particles were generated using the respective plasmid of interest co-transfected 
into HEK293T cells alongside a vector encoding the VSV-G envelope glycoprotein and 
pCMV ΔR8.2 lentiviral packaging construct. Triple transfection used TransIT LT1 (Mirus, 
Cambridge Bioscience, Cambridge, UK) reagent and supernatant containing viral particles 
was collected after 3 days. Target cells were transduced using this viral supernatant and 
Polybrene (Sigma Aldrich) at 1.6 g/mL concentration. Cells were either used as 
oligoclonal populations or subsequently cell lines were selected by puromycin selection. 
Cell proliferation and viability 
 
Resazurin (7-Hydroxy-3H-phenoxazin-3-one-10-oxide sodium salt, Sigma Aldrich) was 
used to determined cell numbers as follows. Resazurin stock solution was added into the 
cell medium at a final concentration of 44 M. After 3-4 h, fluorescence was measured 
using a plate reader, with excitation at 570 nm and detecting emission at 590 nm. 
Autoclaved resazurin (resorufin) was used as a reduced control, resazurin in medium as 
the oxidised control. Blanks and calibration curves were also included in every plate to 
assure the specificity and linearity of response. Each condition was measured in triplicate 
and data presented as mean +/- SD. To study the viability of the 3D printed cells, 
propidium iodide (PI, Sigma) was added to the media at a final 2.5 μM concentration and 
incubated for 30 min in the dark at 37 °C. Nuclear staining of PI was measured by 
Confocal Laser Scanning Microscope Leica SP5 SMD (CLSM, Leica microsystems, 
ESRIC facility). A ratio of apoptotic cells (red) to total cell number was estimated using the 
image analysis software Imaris (Bitplane) for each stack. In some experiments, 
specifically GFP-expressing fluorescent cells were analysed within co-cultured cell 
mixtures. PI concentration was optimised by using the cytotoxic agent etoposide (Sigma 
Aldrich) at a final 10 μM concentration to assure that the dead cell staining is efficient in 
the alginate gel. 
Single cell protein kinase activity analysis 
The kinase translocation reporters pLentiPGK Puro DEST ERK KTR Clover, pLentiPGK 
Puro DEST JNK KTR Clover, pLentiPGK Puro DEST p38 KTR Clover and pLentiPGK 
Puro DEST PKA KTR Clover (Regot et al., 2014), were made by Markus Covert’s 
laboratory (Addgene plasmids # 59150, 59151, 59152 and 59153 respectively). The 
plasmids were incorporated into second generation lentiviral particles and cells were 
transduced using polybrene (Sigma Aldrich) and selected for plasmid incorporation 
(puromycin 500 ng/mL for 6 days). The fluorescently labelled cells were imaged and ratio 
nuclear/cytoplasmic signal was calculated using ImageJ. At least 30 cells were randomly 
selected per condition. 
Recovery of cellular protein and RNA from 3D printed cultures 
3D alginate cultures were washed with ice cold PBS and treated with 7x gel volume of 
pre-chilled chelating agent to sequester divalent cations and dissolve each gel. The 
chelating agents used were EDTA, EGTA or sodium citrate. The resultant culture mixtures 
were incubated on ice for 10 minutes then centrifuged at 4°C and cell pellets lysed for the 
analysis of protein and RNA following previously published methods (Davidson et al., 
2010; Tibarewal et al., 2012). 
Drug sensitivity testing 
Cells were printed in RGDS-alginate on coverslips and transferred into well plates having 
a 2D control using the 3D-printer. Constructs were then exposed to calcium crosslinking 
and incubated for 24 h. Cells were then exposed to specific concentrations of cisplatin 
(Cayman chemicals, Ann Arbor, MI, USA) and temozolomide (Abcam, Cambridge, UK). 
Drug stock solutions were made using NaCl 0.9% and sterile DMSO respectively and 
cisplatin sterilised by filtering. The different drug concentrations were added and left for 72 
hours, then, cell number was assessed using resazurin as previously described. Each 
experimental point was done at least in triplicate. 
  
Results 
Optimising matrices for 3D bioprinting glioblastoma cells 
In this study, 3D bioprinting methods were developed to print cell-laden structures in a 
matrix composed largely of modified alginate. The printer used was a prototype extrusion 
bioprinter provided by Renishaw (Fig. 1B, C). Prior to printing, one or more cell 
populations prepared in adherent culture were mixed into alginate matrices which were 
partially cross-linked with a low CaCl2 concentration (<5 mM). For some experiments, 
other matrix components such as collagen or hyaluronic acid were incorporated as 
minority components (<250 mg/ml). Cells and matrices were rapidly printed (10 minutes – 
1 hour) followed by final cross-linking with higher concentrations of CaCl2 or BaCl2 for 15 
min (Figure 1A, 2A-C). Increasing concentration of CaCl2 generated higher stiffness of 2% 
alginate gels, with exposure to 10 mM CaCl2 giving a mean stiffness of 11.9 kPa and 50 
mM of 25.7 kPa (Fig. 2B and 2C).  
11.9 kPa is at the higher end of the range of stiffness measurements made on tissue 
samples from both glioblastomas and normal brain (Bouchonville et al., 2016; Niu et al., 
2015; Streitberger et al., 2014). We have previously shown the extended invasive 
morphology of U87MG cells suspended in Matrigel (Davidson et al., 2010; Tibarewal et 
al., 2012). To investigate the effects of alginate crosslinking on cell morphology, we 
suspended U87MG cells in a matrix made up of 50% matrigel and final 2% (w/v) RGD-
alginate and applied a range of calcium ion crosslinking concentrations. These 
experiments showed that an increase in matrix cross-linking significantly decreased cell 
spreading and elongation, possibly due to ‘caging in’ by a surrounding densely crosslinked 
matrix (Fig. 2D, 2E) and we elected to use 10mM CaCl2 crosslinking in later printing 
experiments. 
One advantage of alginate over other 3D cell culture matrices is the ability to liquify the 
matrix using chelating agents and recover cells for protein analysis within timescales of a 
few minutes. This contrasts with e.g. matrigel and should allow the retention of many post-
translational protein modifications (Lee et al., 2007; Tibarewal et al., 2012). To confirm 
this, RNA and protein were analysed in samples of U87MG cells recovered from 3D 
alginate cultures and from control adherent cultures (Fig. 3). This analysis showed that 
phosphorylation of two sites, Thr308 and Ser473, on the oncogenic protein kinase AKT 
was retained in all of these samples, particularly after recovery in EGTA. 
Furthermore, we saw highly reproducible recovery of cellular RNA analysed by 
quantitative RT-PCR (Fig. 3). 
Bioprinting diverse cell types in modified alginate 
There is little or no evidence that any human cell type shows receptor-mediated 
engagement with alginate. Accordingly, human cell types which take up extend 
morphologies in vivo instead retain a spherical morphology after deposition within even 
soft alginate matrices with low crosslinking density (Ning et al., 2018; Tabriz et al., 2015). 
To avoid the non-physiological retention of a spherical morphology within the alginate 
matrix, we chemically modified the alginate polymer using carbodiimide conjugation to 
attach an Arg-Gly-Asp peptide sequence (RGD) which is present in many extracellular 
matrix proteins and is bound by several members of the integrin class of cell-surface 
adhesion receptors (Rowley et al., 1999). The comparison of U87MG glioblastoma cells 
and activated MM6 cells bioprinted within unmodified alginate and in RGD-alginate 
showed cell spreading and apparent adhesion in less than 24 hours only within RGD-
alginate (Fig. 4A, B). U87MG cells could be maintained in RGD-alginate matrice whith 
very high viability and proliferate in culture for more than a month (Fig. 4C, D). Therefore, 
RGD-alginate was used in all further experiments unless noted. 
It is recognised that increased shear stress in viscous matrices during printing increases 
cell death (Derby, 2012; Heinrich et al., 2019). As previously seen, in matrices crosslinked 
during and after printing, U87MG cells could be printed within unmodified alginate 
matrices with very high viability and proliferate in culture for more than a month (Figure 
4C, D) (Tabriz et al., 2015). To test whether other cell types retained viability after 3D 
bioprinting, we used propidium iodide exclusion to detect cell death after bioprinting of a 
range of established cell lines in RGD-alginate (Fig. 4E and Fig. 8D). Experimental 
reproducibility and cell viability >90% was seen with glioblastoma cells (U87-MG, DBTRG, 
and 1231N1), and oesophageal adenocarcinoma (OE33, FLO-1) and breast cancer (MDA 
MB-231) cells. Only one breast cancer cell line, MDA-MB-468 which is unusually sensitive 
to EGF-induced apoptosis (Jackson and Ceresa, 2016), showed slightly lower viability but 
still >80%. 
Modelling the glioblastoma tumour microenvironment 
The tumour microenvironment of glioblastoma, as with almost all cancers, contains 
alongside neoplastic cancer cells, large numbers of diverse cell types which influence 
tumour biology and drug sensitivity (Barcellos-Hoff et al., 2013; Charles et al., 2012; 
McMillin et al., 2013). To test our ability to more closely reproduce the complexity of the 
tumour microenvironment by co-printing multiple cell types, we printed U87-MG cells 
together with WI-38 non-immortalised fibroblasts and the macrophage-like Mono-Mac-6 
(MM6) cell line, each expressing a distinct fluorescent protein (yellow, blue and red 
respectively), within an RGD-alginate matrix (Fig. 4F). 
Work to identify tumour repopulating stem cells in glioblastoma has provided patient 
derived cell lines which share many gene expression markers with neural stem cells and 
which closely recapitulate human glioblastoma progression when orthotopically 
xenografted in in mice (Pollard et al., 2009). The suitability of these Glioblastoma Stem 
Cells (GSCs) for bioprinting in RGD-alginate using our method was tested first by 
assessing the viability post printing of these cells by propidium iodide exclusion. Three 
different GSC lines, G144, G166 and G7 (Pollard et al., 2009), all showed viability higher 
than 90% (Fig. 5A) and there was no indication of reduced viability after exposure to the 
divalent cation cross-linkers, calcium and barium. Next, we investigated whether the 
printing process and subsequent culture of these cells in RGD-alginate resulted in an 
increase in the differentiation of these GSC indicating a loss of pluripotency. For this, 
GSCs were cultured for 7 days with and without EGF and FGF either in adherent culture 
or bioprinted in RGD-alginate. As previously described, growth factor withdrawal caused 
the expression of the glial lineage marker GFAP and the loss of the expression of the 
pluripotency marker Nestin in 2D cultures (Fig. 5). However, the 3D bioprinted GSC did 
not show any loss in nestin expression and did not express GFAP, even following growth 
factor withdrawal (Fig. 5B), suggesting that the bioprinting of these cells promotes the 
maintenance of at least some GSC characteristics. 
Bioprinting GSCs in combination with both patient-derived GASCs and with human 
microglia had no adverse effects on cell viability of these cell types (Charles et al., 2012; 
Clavreul et al., 2014) (Fig. 5C). 
Drug sensitivity in 3D bioprinted cancer cells and 2D adherent culture 
U87MG and G7 cells were each cultured alone in both adherent culture and 3D printed in 
multiple well plates using RGD-modified alginate matrix. Cells were exposed to increasing 
concentrations of either cisplatin or temozolomide and viability assessed using resazurin 
(Fig. 6A, B). In 2D adherent cultures, the front line glioblastoma drug temozolomide 
reduced cell numbers with IC50 values of 928.7±1.0 µM and 333.3±1.1 µM for U87MG and 
G7 respectively. When the cells were bioprinted in 3D, the temozolomide IC50 values 
increased by slightly more than two fold to 1994±1.0 µM and 748.8±1.1 µM respectively. 
We then tested the DNA damaging agent cisplatin. This showed that U87MG and G7 
have similar cisplatin IC50s of 8.94±1.09 µM and 10.0±1.1 µM respectively in 2D adherent 
cultures. However, the 3D bioprinted cultures show a significant resistance to cisplatin, 
with an IC50 of 69.8±1.1 µM (U87MG) and 241±1.1 µM (G7). These results show that the 
3D bioprinted constructs are very strongly resistance to cisplatin, a drug which has failed 
in several clinical trials for glioblastoma (EORTC, 1991; Grossman et al., 2003). 
Next, we aimed to test how incorporating macrophage-like stromal cells within the 3D 
printed constructs affected drug sensitivity. Either G7 or U87MG cells were 3D printed 
with and without 20% by cell number MM6 cells, PMA-activated MM6 (aMM6) or human 
microglia mixed with the glioblastoma cells. The bioprinted structures were then treated 
with IC50 concentrations of temozolomide or vehicle and viability assessed by DRAQ7 
staining and microscopy. This data shows that for U87MG, the presence of MM6 
decrease the sensitivity of the drug, with the surviving fraction increasing from 50.1±6.7% 
to 73.8±5.2%. On the other hand, aMM6 did not decrease the sensitivity to temozolomide, 
maintaining the surviving fraction in 53.1±6.7%. G7 cells however, did not display this 
effect, with temozolomide sensitivity increasing modestly when they were co-printed with 
MM6, with cell surviving fraction decreasing from 56.0±3.53 % to 41.9±5.75 %. Similarly to 
U87MG, aMM6 did not significantly alter the surviving fraction, which remained 57.1±6.8 
%. When primary human microglia were co-printed with the G7 cells, the percentage of 
viable cells did not significantly change relative to only G7, suggesting that the choice of 
relevant stromal cells can impact substantially on the outcome of these experiments. 
Single cell protein kinase activation analysis 
As a tool to study cell signalling at the single cell level, protein kinase reporters were used 
to assess the activity of the ERK protein kinases (Figure 7) as well as p38, JNK and PKA 
(data not shown). These previously described biosensors are based on fluorescence 
translocation driven by their phosphorylation by specific protein kinases, with specificity 
provided both by phosphorylation site sequence specificity and independently by kinase 
docking sites within each reporter. They display fluorescence in the nucleus when the 
reporter is unphosphorylated due to low kinase activity and display fluorescence in the 
cytoplasm when the reporter is phosphorylated due to higher kinase activity (Regot et al., 
2014).  
Figure 7A shows the behaviour of U87MG cells expressing the ERK KTR mClover 
biosensor, which appeared similarly concentrated in the cytoplasm and nucleus of most 
cells growing in 10% FBS. We observed a fluorescence translocation when cells were 
cultured in serum free medium, with fluorescence being nuclear in most cells. Conversely, 
when cells were exposed to medium with 20% FBS most cells displayed a largely 
cytoplasmic localisation of the reporter. To assess the kinase activity in a co-culture of 
glioblastoma cells with MM6 cells, polyclonal populations of U87MG cells expressing 
ERK-KTR-mClover were incubated either in adherent culture or 3D bioprinted either alone 
or in combination with MM6 or aMM6 cells. Images were taken using a two photon 
microscope and fluorescence ratio between nuclear and cytoplasmic fluorescence 
measured (Fig. 7B). This showed that biosensor analysis in these 3D printed constructs 
indicates an increase in the activation status of the ERK kinases when the cells were co-
printed with aMM6 or with MM6. This ability to analyse signalling in individual printed cells 
supports the expectation that the presence of stromal cells can activate cell signalling 
pathways in 3D co-printed constructs. 
Finally, in testing more complex spatial arrangements within printed constructs, tumour 
cells were positioned centrally with a surrounding layer of mixed tumour and stromal cells. 
Two-layered and three-layered structures were 3D printed using the sequential cross-
linking method and modified alginate (Figure 8A, B). This was reproducible when 
bioprinting multiple well plates and also showed that the same number of cells can be 
deposited when compared to deposition of a cell suspension on plastic with only 
marginally higher variability in cell number (Fig. 8C and 8D). 
  
Discussion 
We present 3D bioprinting methods using bioinks based upon modified alginate to prepare 
tumour models incorporating tumour and stromal cells from glioblastoma. We show that 
crosslinking alginate with higher concentrations of divalent cations which should have 
benefits in terms of structural integrity and resolution can inhibit cell spreading and cell-
cell interaction leading to unphysiological results. For this reason, and due to the lower 
stiffness of brain tumour tissue (mostly in the range 1-10 kPa (Bouchonville et al., 2016; 
Niu et al., 2015; Streitberger et al., 2014)), we concentrated on the use of lower 
concentrations of alginate and cross-linker, generally 2% alginate and 10mM Ca2+. 
Similarly, to improve cell-cell interaction, we used RGD-peptide conjugated alginate, and 
in some cases additional hyaluronic acid, to promote the engagement of cells with the 
surrounding matrix. 
When the 3D bioprinted glioblastoma cell constructs were used to test sensitivities to 
temozolomide and cisplatin, a modest drug resistance relative to adherent culture was 
observed for temozolomide, but a very substantial resistance for cisplatin (Figure 6). 
Relating to this data, it is notable that cisplatin was previously put through several clinical 
trials for high grade glioma without success, but gives promising cytotoxicity data in 2D 
and some 3D cultures, including collagen gels and 3D spheroids/neurospheres (Ahmed et 
al., 2018; Berger et al., 2018; Yuki et al., 1994; Yung et al., 1982). Investigation into the 
factors which contribute to this cisplatin resistance in 3D bioprinted culture may help 
inform future 3D culture models of glioblastoma. 
Whilst attempting to develop standardized cultured cell-based models which more closely 
represent healthy and diseased tissue, the impact and value of some modified 
characteristics of the model are often unclear without e.g. impractical deep gene 
expression analysis. However, as more highly evolved models are produced and better 
characterisation of these models is performed, it should be possible cost-effectively to 
match individual models to individual applications. The methods described here, which 
support the spatial organisation of multiple cell types which contribute to the glioblastoma 
environment and allow recovery of protein and RNA as well as analysis of signalling at the 
single cell level, should accelerate the provision of improved models of glioblastoma. 
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Figure Legends 
 
Fig. 1. (A) Schematic representation of 3D bioprinting with alginate. The printable bioink is 
prepared by mixing of cells and hydrogel matrix followed by pre-crosslinking with low 
concentration divalent cation exposure. The printed construct achieves stability by final 
crosslinking with higher divalent cation concentration. (B) The equipment used for the 3D 
printing experiments shows the bioprinter with the controlling computer (left) and the 8-valve 
syringe pump (right) driving the deposition system extruding the bioink via (C). The printer 
has 6 print head nozzles. All bioprinting experiments were conducted in a sterile laminar flow 
cabinet. 
 
Fig. 2. Tuning of alginate stiffness influences embedded cell behaviour. (A) Representative 
2% RGD-alginate constructs crosslinked calcium chloride (CaCl
2
) for 15 min and analysed 
as shown in (B) and (C).  (B)  Representative dynamic mechanical analysis (DMA) plot. C. 
The stiffness comparison of constructs crosslinked with 10 mM and 50 mM CaCl
2
. (D) 
Representative brightfield images of U87MG cells embedded in 2 % RGD-alginate with 
varying crosslinking concentration of CaCl
2
 (top panel). Examples of extended/spread cells 
and rounded cells are identified with red and black arrows respectively. The zoomed images 
again illustrate spread and rounded cells (bottom panels). (E) Quantification of cell spreading 
and rounded cells from D. * = p < 0.05 ** = p < 0.01, scale bar 20 µm. Error bars: S.E.M. 
 
Fig. 3. Recovery or protein and RNA from cells embedded in alginate. U87MG cells were 
suspended into 2% alginate at a concentration of 10
6
 cells/mL, crosslinked with 10 mM 
CaCl
2
 for 30 minutes and incubated for 24 h in complete medium. Control cells were 
maintained in 2D adherent culture in parallel. To block the phosphorylation of AKT, the small 
molecule pan-isoform inhibitor of class I PI3Ks, GDC0941/pictilisib was added to some 
cultures. These 3D alginate cultures were then washed with ice cold PBS and treated with 
7x gel volume of the indicated concentrations of pre-chilled chelating agent to sequester 
divalent cations and dissolve each gel. The culture mixtures were incubated on ice for 10 
minutes then centrifuged at 4°C and cell pellets lysed for the analysis of protein and RNA. 
Proteins were separated by SDS-PAGE and analysed either by total protein stain (A) or 
immunoblotting to reveal retained protein abundance and phosphorylation (B). RNA samples 
were analysed by standard reverse transcriptase (RT)-PCR with and without RT treatment 
(C) and by quantitative real-time RT-PCR (D), again with and without RT. 
 
Fig. 4. Morphology and viability of printed cells. (A and B) U87MG-GFP cells (green) and 
aMM6-mCherry cells (red) were printed in (A) unmodified alginate and (B) RGDS-alginate. 
(C and D) U87MG cells expressing GFP show long term viability and proliferation at (C) day 
1 post-printing and (D) day 26 post-printing. In (C) and (D) green fluorescent cells were 
printed and cell death assessed by uptake of Propidium Iodide (PI - Red). (E) shows the 
viability of different cell lines printed in RGD-alginate. Cells treated with the cytotoxic 
topoisomerase inhibitor Etoposide at 10 mM are included as a control. Mean +/- SEM. (F) 
shows a co-printed construct of labelled U87MG, WI38 and MM6 cells expressing three 
different fluorescent proteins, EYFP, Cerulean and mCherry respectively. 
 
Fig. 5. Glioma Stem Cell (GSC) lines. (A) Viability of the GSC lines G144, G166 and G7 24 
h after bioprinting assessed by propidium iodide exclusion. Mean +/- SEM. (B) Nestin and 
GFAP staining showing that G7 cells retain the expression of the stem cell marker Nestin 
even after removal of FGF and EGF. (C) G7 glioblastoma stem cells expressing mCherry 
(red), primary human microglia expressing GFP (green) and GASC expressing cerulean 
(blue) were co-printed and photographed 6 hours later. The scale bar represents 100 m.  
 
Fig. 6. Drug dose response of glioblastoma cells in 3D bioprinted models. U87MG or G7 cells 
were cultured in 2D or 3D printed in RGDS-Alginate and the were treated with increasing 
concentrations of either (A) cisplatin or (B) temozolomide for 72 hours. Calibration curves were 
included and the experiment  was performed 3 times. (C) U87MG-EGFP and (D and E) G7-
EGFP, were 3D printing either alone or in coculture with either MM6 cells, aMM6 cells or primary 
human microglia. Constructs were then treated with DMSO or temozolomide for 72 h at their 
respective IC50 concentrations. Viability specifically of glioblastoma cells was calculated using 
microscopy and Imaris software. Dead cells were stained with DRAQ7.  Error bar: SEM, ANOVA 
analysis was performed. * p = 0.1, *** p = 0.001, n.s. = non-significant 
 
Figure 7. Single cell kinase reporters. U87MG expressing the biosensor ERK-KTR-mClover 
in (A) prolonged 10% FBS culture (Basal - left), cultured in serum-free medium for 4 hours 
(middle) or with 20 % FBS for 4 hours (right). (B) The ratio between cytoplasmic and nuclear 
fluorescence intensity, represented in logarithmic scale for U87MG cells 3D printed in RGD 
alginate alone or in co-culture with MM6 and aMM6 for ERK KTR is shown. Data are 
represented as mean and showing the maximum and minimum values and the 25th to 75th 
percentile. 30 cell images were quantified for each condition using Imaris. Data are 
represented as the logarithm of the ratio between cytoplasm and nuclear fluorescence 
intensity. Difference analysed using ANOVA. * p < 0.01, **p < 0.001. 
 
Fig. 8. Bioprinted constructs. (A) A two-layered model with a core of cancer cells surrounded 
by stromal cells, schematic (Left), printed construct side (middle) and from above (right). (B) 
A schematic of a 3 layered model, core of cancer, surrounded by mix of  cancer cells and 
stromal cells with an exterior final layer of stromal cells (left), printed construct (middle and 
right). (C) 3 layer printed constructs in 12 well plate, top view (left) and side view (right). (D) 
U87MG cells were either plated in standard 2D adherent cell culture or 3D bioprinted with 
and without the induction of cell death using 10 M etoposide. Actively metabolising cell 
number was assessed by resazurin reduction. The data show mean +/- SEM from 3 
independent experiments. 
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